Saturday, May 24, 2014

Antidotes for target specific oral anticoagulants: coming soon

Currently available options for reversal of TSOACs are limited. However, specific antidotes are in the pipeline and were the subject of this recent review.

They include:

PRT064445 (Portola Pharmaceuticals)

A recombinant Xa variant. Reverses anti Xa agents.

aDabi-Fab (Boehringer Ingelheim)

A humanized Fab fragment for reversal of dabigatran.

PER977 (Perosphere Inc and Daiichi Sankyo)

A small synthetic molecule which is a broad spectrum antidote, binding TSOACs, fondaparinux and low–molecular-weight heparins.

No comments: